Lucira Health, Inc. (LHDX)

NASDAQ: LHDX · IEX Real-Time Price · USD
2.11
-0.23 (-9.83%)
At close: Aug 19, 2022 4:00 PM
2.07
-0.04 (-1.90%)
After-hours: Aug 19, 2022 7:30 PM EDT
-9.83%
Market Cap 84.62M
Revenue (ttm) 192.72M
Net Income (ttm) -43.91M
Shares Out 40.11M
EPS (ttm) -0.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,972
Open 2.34
Previous Close 2.34
Day's Range 2.05 - 2.43
52-Week Range 1.36 - 10.65
Beta n/a
Analysts Sell
Price Target 3.57 (+69.2%)
Earnings Date Aug 15, 2022

About LHDX

Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and ... [Read more...]

Industry Medical Devices
IPO Date Feb 5, 2021
Employees 219
Stock Exchange NASDAQ
Ticker Symbol LHDX
Full Company Profile

Financial Performance

In 2021, Lucira Health's revenue was $93.06 million, an increase of 34,492.94% compared to the previous year's $269,000. Losses were -$64.83 million, 73.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for LHDX stock is "Sell." The 12-month stock price forecast is 3.57, which is an increase of 69.19% from the latest price.

Price Target
$3.57
(69.19% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Lucira Health Announces Second Quarter 2022 Results and Provides Business Updates

EMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commerc...

Lucira Announces Health Canada Authorization of First and Only 99% Accurate At-Home Covid & Flu Test

EMERYVILLE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commerc...

Lucira Health to Announce Second Quarter 2022 Financial Results

EMERYVILLE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative a...

Lucira Health Announces First Quarter 2022 Results and Business Update

EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company focused on the development and commerci...

Lucira Health files for FDA authorization of first COVID-19 & flu at-home molecular test

Lucira Health Inc. LHDX, -6.02% said Thursday it has filed for Food and Drug Administration authorization for its first-of-its-kind COVID-19 & flu at-home molecular test. The medical tech company, which...

Lucira Files for Authorization of First-of-its-Kind COVID-19 & Flu At-Home Molecular Test

This first ever at-home COVID-19 and flu test is designed to allow individuals to differentiate between the infections and seek appropriate treatment within 30 minutes from home This first ever at-home ...

Lucira Health to Participate in Bank of America 2022 Healthcare Conference

EMERYVILLE, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative an...

Lucira Health to Announce First Quarter 2022 Financial Results

EMERYVILLE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative ...

Grab Market Momentum With 5 Top Rising P/E Stocks

Forget undervalued stocks, play these top-ranked stocks (BKE, LHDX, DOOO, LOVE, KTB) with rising P/E.

Other symbols: BKEDOOOLOVE

LUCIRA HEALTH AND USA BOXING ANNOUNCE EXCLUSIVE PARTNERSHIP FOR THE 2022 SEASON

Lucira is the official COVID-19 test provider of USA Boxing athletes and staff and will commit $5 of support to the organization for each test purchased by fans EMERYVILLE, Calif. , April 21, 2022 /PRNe...

Lucira Health Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative ...

Looking for a Growth Stock? Why It is Time to Focus on Lucira Health (LHDX)

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Lucira Health (LHDX).

LHDX INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Lucira Health, Inc. Investors with Losses to Inquir...

New York, New York--(Newsfile Corp. - April 1, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Lucira He...

Lucira Donates Rapid Molecular At-Home COVID-19 Test Kits to Protect the Safety of Tonga Red Cross Society Workers

COVID-19 Comes to Isolated Pacific Island of Tonga  And Cases Soar After Volcanic Eruption and Tsunami EMERYVILLE, Calif. , March 31, 2022 /PRNewswire/ -- Lucira Health, Inc. ("Lucira Health" or "Lucira...

Lucira Health's PCR-Quality At-Home COVID-19 Test Now Available Direct to Consumers in Canada

Lucira's molecular test provides PCR-quality results in 30 minutes in a simple single-use test Lucira was the first at-home COVID-19 test authorized in Canada and has been used in public health programs...

Lucira Health Announces Fourth Quarter and Full Year 2021 Results and Reaffirms 2022 Financial Outlook

EMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company focused on the development and commer...

Lucira Health to Announce Fourth Quarter 2021 Financial Results

EMERYVILLE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”) (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of t...

Lucira Health Shares Fall After Announcing Debt Facility Of $80M

Lucira Health Inc LHDX has entered into a debt facility of up to $80 million with Hercules Capital and Silicon Valley Bank.  Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Lucira™ Health Commits 2 Million At-Home Molecular COVID-19 Test Kits on Amazon

EMERYVILLE, Calif., Feb. 3, 2022 /PRNewswire/ -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focusing on the development and commercialization of trans...

Lucira™ Check-It PCR-Quality, At-Home Molecular COVID-19 Test Now Available in the Optum Store

EMERYVILLE, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of t...

Lucira Health Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2021 and Provides Business Update

EMERYVILLE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and i...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lucira Health, Inc. - LHDX

NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lucira Health, Inc. ("Lucira" or the "Company") (NASDAQ: LHDX). Such investors are advised to conta...

Lucira Health and Co-Defend/Co-Protect Announce Expanded Partnership for 2022

EMERYVILLE, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and i...

Lucira Health Announces Expanded Partnership with Switch Health to Increase Canadians' Access to At-Home Molecular CO...

EMERYVILLE, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and i...

TOP RANKED ROSEN LAW FIRM Encourages Lucira Health, Inc. Investors with Losses to Inquire About Class Action Investig...

NEW YORK, Dec. 20, 2021 /PRNewswire/ -- WHY: New York, N.Y., December 19, 2021.